Redmile reports 6.7% stake in Stoke Therapeutics

Stoke Therapeutics, Inc. ownership update: an amended Schedule 13G/A shows Redmile Group, LLC and related entities report beneficial ownership of common stock as of March 31, 2026.

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. ownership update: an amended Schedule 13G/A shows Redmile Group, LLC and related entities report beneficial ownership of common stock as of March 31, 2026. The filing states Redmile Group, LLC and Jeremy C. Green each have 4,164,120 shares (representing 6.7% of the class) and Redmile Biopharma Investments III, L.P. holds 3,505,612 shares (5.6%), based on 62,240,347 shares outstanding as of March 31, 2026. The filing attributes shared voting and dispositive power to Redmile for these holdings and includes standard disclaimers of beneficial ownership except for pecuniary interest.

Insights

Institutional Ownership Analyst

Redmile reports mid-single-digit stakes in Stoke and shared voting/dispositive power.

Redmile Group, LLC is disclosed with 4,164,120 shares and shared voting and dispositive power, representing 6.7% of the outstanding common stock as of March 31, 2026. The filing cites the issuer's Schedule 14A for the outstanding share count.

Potential implications depend on Redmile's future filings and voting decisions; subsequent Schedule 13D/13G amendments or Form 4s would clarify active engagement. Cash‑flow treatment and upcoming actions are timing not specified in the provided excerpt.

Securities Compliance Specialist

Amendment clarifies beneficial ownership and attribution for compliance purposes.

The amendment documents attribution of shares held by Redmile-managed funds and shows standard disclaimers by Redmile and Mr. Green. It references shared control over 4,164,120 shares and allocates 3,505,612 shares to a specific fund.

From a compliance perspective, the filing updates Item 4 and attaches signature attestations dated May 15, 2026. Watch for any future changes in ownership class or voting power reported in later SEC filings.

Key Figures

Redmile Group shares: 4,164,120 shares Jeremy C. Green shares: 4,164,120 shares Redmile Biopharma III shares: 3,505,612 shares +3 more

6 metrics

Redmile Group shares 4,164,120 shares Beneficial ownership reported for Redmile Group, LLC as of March 31, 2026

Jeremy C. Green shares 4,164,120 shares Beneficial ownership reported for Jeremy C. Green as of March 31, 2026

Redmile Biopharma III shares 3,505,612 shares Beneficial ownership reported for Redmile Biopharma Investments III, L.P. as of March 31, 2026

Percent of class (Redmile / Green) 6.7% Percent based on 62,240,347 shares outstanding as of March 31, 2026

Percent of class (Fund) 5.6% Percent for Redmile Biopharma Investments III, L.P. based on same outstanding share count

Shares outstanding referenced 62,240,347 shares Shares outstanding cited from the Issuer's Schedule 14A as of March 31, 2026

Key Terms

Schedule 13G/A, beneficial ownership, shared dispositive power, pecuniary interest disclaimer

4 terms

Schedule 13G/A regulatory

"Amendment No. 6 and Item 2 identify this filing as an amended Schedule 13G/A"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficial ownership financial

"Item 4 lists 'Amount beneficially owned' and percent of class calculations"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

shared dispositive power regulatory

"Item 4(c)(iv) discloses 'Shared power to dispose or to direct the disposition of' the shares"

pecuniary interest disclaimer legal

"Redmile and Mr. Green 'disclaim beneficial ownership... except to the extent of its or his pecuniary interest'"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Redmile Group report in STOK?

Redmile Group, LLC reports beneficial ownership of 4,164,120 shares, equal to 6.7% of common stock based on 62,240,347 shares outstanding as of March 31, 2026. The filing attributes shared voting and dispositive power to Redmile for these shares.

How many shares does Jeremy C. Green beneficially own in STOK?

Jeremy C. Green is reported with beneficial ownership of 4,164,120 shares, representing 6.7% of the class as of March 31, 2026. The filing states shared voting and dispositive power and includes a standard pecuniary-interest disclaimer.

What holdings are reported for Redmile Biopharma Investments III, L.P.?

Redmile Biopharma Investments III, L.P. is reported to hold 3,505,612 shares, equal to 5.6% of the common stock based on the issuer's 62,240,347 shares outstanding as of March 31, 2026, with shared voting and dispositive power.

Does the amendment change voting or disposition authority for these shares?

The amendment states Redmile and Jeremy C. Green have shared voting and shared dispositive power over the reported shares. It attributes control to Redmile as investment manager of the Redmile Funds and includes disclaimers limiting claimed beneficial ownership to pecuniary interest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:16 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 6)

Stoke Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

86150R107

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 86150R107

1

Names of Reporting Persons

Redmile Group, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,164,120.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,164,120.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,164,120.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.7 %

12

Type of Reporting Person (See Instructions)

IA, OO

Comment for Type of Reporting Person: The information in Item 4 relating to the shares of the Issuer's common stock ("Common Stock") that are or may be deemed beneficially owned by Redmile Group, LLC ("Redmile") is incorporated herein by reference. Percentage based on 62,240,347 shares of Common Stock outstanding as of March 31, 2026, as reported by the Issuer in its Definitive Proxy Statement on Schedule 14A filed with the SEC on April 22, 2026 (the "Schedule 14A").

SCHEDULE 13G

CUSIP Number(s): 86150R107

1

Names of Reporting Persons

Jeremy C. Green

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,164,120.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,164,120.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,164,120.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.7 %

12

Type of Reporting Person (See Instructions)

HC, IN

Comment for Type of Reporting Person: The information in Item 4 relating to the shares of Common Stock that are or may be deemed beneficially owned by Jeremy C. Green is incorporated herein by reference. Percentage based on 62,240,347 shares of Common Stock outstanding as of March 31, 2026, as reported by the Issuer in the Schedule 14A.

SCHEDULE 13G

CUSIP Number(s): 86150R107

1

Names of Reporting Persons

Redmile Biopharma Investments III, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,505,612.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,505,612.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,505,612.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.6 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Percentage based on 62,240,347 shares of Common Stock outstanding as of March 31, 2026, as reported by the Issuer in the Schedule 14A.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Stoke Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 45 Wiggins Ave, Bedford, MA 01730
Item 2.
(a)	Name of person filing: Redmile Group, LLC Jeremy C. Green Redmile Biopharma Investments III, L.P.
(b)	Address or principal business office or, if none, residence: Redmile Group, LLC 900 Larkspur Landing Circle, Suite 270 Larkspur, California 94939 Jeremy C. Green c/o Redmile Group, LLC (NY Office) 45 W. 27th Street, Floor 11 New York, NY 10001 Redmile Biopharma Investments III, L.P. c/o Redmile Group, LLC 900 Larkspur Landing Circle, Suite 270 Larkspur, California 94939
(c)	Citizenship: Redmile Group, LLC: Delaware Jeremy C. Green: United Kingdom Redmile Biopharma Investments III, L.P.: Delaware
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 86150R107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Redmile Group, LLC - 4,164,120 (1) Jeremy C. Green - 4,164,120 (1) Redmile Biopharma Investments III, L.P. - 3,505,612
(b)	Percent of class: Redmile Group, LLC - 6.7% (2) Jeremy C. Green - 6.7% (2) Redmile Biopharma Investments III, L.P. - 5.6% (2)
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Redmile Group, LLC - 0 Jeremy C. Green - 0 Redmile Biopharma Investments III, L.P. - 0
	(ii) Shared power to vote or to direct the vote: Redmile Group, LLC - 4,164,120 (1) Jeremy C. Green - 4,164,120 (1) Redmile Biopharma Investments III, L.P. - 3,505,612
	(iii) Sole power to dispose or to direct the disposition of: Redmile Group, LLC - 0 Jeremy C. Green - 0 Redmile Biopharma Investments III, L.P. - 0
	(iv) Shared power to dispose or to direct the disposition of: Redmile Group, LLC - 4,164,120 (1) Jeremy C. Green - 4,164,120 (1) Redmile Biopharma Investments III, L.P. - 3,505,612 (1) As of March 31, 2026, Redmile's and Jeremy C. Green's beneficial ownership of Common Stock is comprised of 4,164,120 shares of Common Stock. All of such shares of Common Stock are directly owned by certain investment vehicles, including Redmile Biopharma Investments III, L.P., for which Redmile is the investment manager (the "Redmile Funds"). Redmile may be deemed to beneficially own these securities in its capacity as the investment manager with discretion to vote and dispose of all shares of Common Stock held by the Redmile Funds. Mr. Green also may be deemed to beneficially own these securities as the principal of Redmile. Redmile and Mr. Green each disclaim beneficial ownership of these securities, except to the extent of its or his pecuniary interest in such securities, if any. (2) Percentage based on 62,240,347 shares of Common Stock outstanding as of March 31, 2026, as reported by the Issuer in the Schedule 14A.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See the response to Item 4.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Redmile Group, LLC

Signature:	/s/ Jeremy C. Green
Name/Title:	Managing Member
Date:	05/15/2026

Jeremy C. Green

Signature:	/s/ Jeremy C. Green
Name/Title:	Jeremy C. Green
Date:	05/15/2026

Redmile Biopharma Investments III, L.P.

Signature:	/s/ Jeremy C. Green
Name/Title:	Managing Member of Redmile Biopharma Investments III (GP), LLC, general partner of Redmile Biopharma Investments III, L.P.
Date:	05/15/2026